{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:16:36Z","timestamp":1791303396050,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T00:00:00Z","timestamp":1507766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>There has been renewed interest of late in the role of modeling-based formation (MBF) during osteoporosis therapy. Here we describe early effects of an established anabolic (teriparatide) versus antiresorptive (denosumab) agent on remodeling-based formation (RBF), MBF, and overflow MBF (oMBF) in human transiliac bone biopsies. Postmenopausal women with osteoporosis received subcutaneous teriparatide (n\u2009=\u200933, 20\u2009\u03bcg\/d) or denosumab (n\u2009=\u200936, 60\u2009mg once\/6 months), open-label for 6 months at 7 US and Canadian sites. Subjects received double fluorochrome labeling at baseline and before biopsy at 3 months. Sites of bone formation were designated as MBF if the underlying cement line was smooth, RBF if scalloped, and oMBF if formed over smooth cement lines adjacent to scalloped reversal lines. At baseline, mean RBF\/bone surface (BS), MBF\/BS, and oMBF\/BS were similar between the teriparatide and denosumab groups in each bone envelope assessed (cancellous, endocortical, periosteal). All types of formation significantly increased from baseline in the cancellous and endocortical envelopes (differences p\u2009&amp;lt;\u20090.001) with teriparatide (range of changes 2.9- to 21.9-fold), as did MBF in the periosteum (p\u2009&amp;lt;\u20090.001). In contrast, all types of formation were decreased or not significantly changed with denosumab, except MBF\/BS in the cancellous envelope, which increased 2.5-fold (difference p\u2009=\u20090.048). These data highlight mechanistic differences between these agents: all 3 types of bone formation increased significantly with teriparatide, whereas formation was predominantly decreased or not significantly changed with denosumab, except for a slight increase in MBF\/BS in the cancellous envelope. \u00a9 2017 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.3309","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T10:56:36Z","timestamp":1507805796000},"page":"298-306","source":"Crossref","is-referenced-by-count":80,"title":["Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study"],"prefix":"10.1093","volume":"33","author":[{"given":"David W","family":"Dempster","sequence":"first","affiliation":[{"name":"Department of Pathology and Cell BiologyCollege of Physicians and Surgeons of Columbia UniversityNew YorkNYUSA"},{"name":"Regional Bone CenterHelen Hayes HospitalWest HaverstrawNYUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Regional Bone CenterHelen Hayes HospitalWest HaverstrawNYUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R","family":"Recker","sequence":"additional","affiliation":[{"name":"Department of MedicineDivision of EndocrinologySchool of MedicineCreighton UniversityOmahaNEUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques P","family":"Brown","sequence":"additional","affiliation":[{"name":"Rheumatology and Bone Diseases Research GroupCHU de Qu\u00e9bec (CHUL)Research Centre and Department of MedicineLaval UniversityQuebec CityCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P","family":"Recknor","sequence":"additional","affiliation":[{"name":"United Osteoporosis CentersGainesvilleGAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Michael","family":"Lewiecki","sequence":"additional","affiliation":[{"name":"New Mexico Clinical Research & Osteoporosis CenterAlbuquerqueNMUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D","family":"Miller","sequence":"additional","affiliation":[{"name":"Department of MedicineColorado Center for Bone ResearchLakewoodCOUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhaker D","family":"Rao","sequence":"additional","affiliation":[{"name":"Bone & Mineral Research LaboratoryHenry Ford HospitalDetroitMIUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Kendler","sequence":"additional","affiliation":[{"name":"Department of Medicine (Endocrinology)University of British ColumbiaVancouverCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lindsay","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell BiologyCollege of Physicians and Surgeons of Columbia UniversityNew YorkNYUSA"},{"name":"Regional Bone CenterHelen Hayes HospitalWest HaverstrawNYUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Krege","sequence":"additional","affiliation":[{"name":"Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahangir","family":"Alam","sequence":"additional","affiliation":[{"name":"Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A","family":"Taylor","sequence":"additional","affiliation":[{"name":"Musculoskeletal and Men's HealthLilly USA LLCIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E","family":"Melby","sequence":"additional","affiliation":[{"name":"INC Research\/inVentiv HealthRaleighNCUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie A","family":"Ruff","sequence":"additional","affiliation":[{"name":"Musculoskeletal and Men's HealthLilly USA LLCIndianapolisINUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"issue":"983","key":"2024021014392167200_jbmr3309-bib-0001","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/206489a0","article-title":"Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling","volume":"206","author":"Hattner","year":"1965","journal-title":"Nature"},{"issue":"2","key":"2024021014392167200_jbmr3309-bib-0002","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"issue":"3","key":"2024021014392167200_jbmr3309-bib-0003","first-page":"232","article-title":"Cancellous bone minimodeling-based formation: a Frost, Takahashi legacy","volume":"7","author":"Jee","year":"2007","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"4","key":"2024021014392167200_jbmr3309-bib-0004","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ar.1092260402","article-title":"Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolff's law: the bone modeling problem","volume":"226","author":"Frost","year":"1990","journal-title":"Anat Rec"},{"issue":"8","key":"2024021014392167200_jbmr3309-bib-0005","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s11999-009-0776-z","article-title":"Tibia adaptation after fibula harvesting: an in vivo quantitative study","volume":"467","author":"Taddei","year":"2009","journal-title":"Clin Orthop Relat Res"},{"issue":"2","key":"2024021014392167200_jbmr3309-bib-0006","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S8756-3282(02)00947-X","article-title":"Trabecular minimodeling in human iliac bone","volume":"32","author":"Kobayashi","year":"2003","journal-title":"Bone"},{"issue":"2","key":"2024021014392167200_jbmr3309-bib-0007","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1359\/JBMR.041114","article-title":"Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling","volume":"20","author":"Riggs","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"21","key":"2024021014392167200_jbmr3309-bib-0008","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2014the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2024021014392167200_jbmr3309-bib-0009","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1359\/jbmr.060314","article-title":"Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis","volume":"21","author":"Ma","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024021014392167200_jbmr3309-bib-0010","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide","volume":"21","author":"Lindsay","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2024021014392167200_jbmr3309-bib-0011","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024021014392167200_jbmr3309-bib-0012","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1523-1755.2005.00464.x","article-title":"Significance of minimodeling in dialysis patients with adynamic bone disease","volume":"68","author":"Ubara","year":"2005","journal-title":"Kidney Int"},{"issue":"4","key":"2024021014392167200_jbmr3309-bib-0013","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1359\/jbmr.070104","article-title":"Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium","volume":"22","author":"Lindsay","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024021014392167200_jbmr3309-bib-0014","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1210\/jc.2015-4181","article-title":"Differential effects of teriparatide and denosumab on intact PTH and bone formation indices: AVA Osteoporosis Study","volume":"101","author":"Dempster","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021014392167200_jbmr3309-bib-0015","first-page":"491","volume-title":"Principles and practice of endocrinology and metabolism","author":"Dempster","year":"1995"},{"issue":"10","key":"2024021014392167200_jbmr3309-bib-0016","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2024021014392167200_jbmr3309-bib-0017","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"issue":"19","key":"2024021014392167200_jbmr3309-bib-0018","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"2024021014392167200_jbmr3309-bib-0019","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/jbmr.5650071216","article-title":"Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women","volume":"7","author":"Balena","year":"1992","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2024021014392167200_jbmr3309-bib-0020","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.bone.2011.01.012","article-title":"Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis","volume":"48","author":"Ma","year":"2011","journal-title":"Bone"},{"issue":"11","key":"2024021014392167200_jbmr3309-bib-0021","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension","volume":"98","author":"Bone","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2024021014392167200_jbmr3309-bib-0022","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos Int"},{"issue":"7","key":"2024021014392167200_jbmr3309-bib-0023","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2024021014392167200_jbmr3309-bib-0024","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/jbmr.2855","article-title":"Denosumab reduces cortical porosity of the proximal femoral shaft in postmenopausal women with osteoporosis","volume":"31","author":"Zebaze","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2024021014392167200_jbmr3309-bib-0025","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bone.2011.03.769","article-title":"Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody","volume":"49","author":"Kostenuik","year":"2011","journal-title":"Bone"},{"issue":"2","key":"2024021014392167200_jbmr3309-bib-0026","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2011.04.001","article-title":"Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys","volume":"49","author":"Ominsky","year":"2011","journal-title":"Bone"},{"issue":"8","key":"2024021014392167200_jbmr3309-bib-0027","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/jbmr.2825","article-title":"Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 months in the SHOTZ Study","volume":"31","author":"Dempster","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024021014392167200_jbmr3309-bib-0028","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1210\/jc.2012-1262","article-title":"Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial","volume":"97","author":"Dempster","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2024021014392167200_jbmr3309-bib-0029","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/jbmr.2804","article-title":"A longitudinal study of skeletal histomorphometry at 6 and 24 months across four bone envelopes in postmenopausal women with osteoporosis receiving teriparatide or zoledronic acid in the SHOTZ trial","volume":"31","author":"Dempster","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024021014392167200_jbmr3309-bib-0030","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1210\/jc.2015-3698","article-title":"Effect of teriparatide on bone formation in the human femoral neck","volume":"101","author":"Cosman","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024021014392167200_jbmr3309-bib-0031","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/jbmr.3051","article-title":"Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis","volume":"32","author":"Cosman","year":"2017","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.3309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/2\/298\/56653729\/jbmr3309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/33\/2\/298\/56653729\/jbmr3309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:00:18Z","timestamp":1710342018000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/33\/2\/298-306\/7605757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,10,12]]},"published-print":{"date-parts":[[2018,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.3309","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2,1]]},"published":{"date-parts":[[2017,10,12]]}}}